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Asymptomatic rectal Chlamydia trachomatis (CT) infections are common among men who 
have sex with men (MSM) (1), and frequently exist apart from urethral infections: up to 88% 
of those with rectal CT are negative at the urethra (2). The Centers for Disease Control 
(CDC) recommends rectal screening for CT among MSM at least yearly, and for those 
positive, rescreening in ∼3 months due to a substantial rate of repeat infections (3). 
Currently, CDC treatment recommendations for asymptomatic rectal infections include 
either azithromycin 1 g orally as a single dose, or doxycycline 100 mg orally bid for 7 days 
(3). Treatment recommendations for symptomatic proctitis and severe proctocolitis differ 
because pathogens other than C. trachomatis, including Neisseria gonorrhoeae and herpes 
simplex virus, can cause these syndromes. Severe disease also suggests lymphogranuloma 
venereum, caused by LGV strains of C. trachomatis, for which 21 days of doxycycline is 
recommended.
Notwithstanding the CDC guidelines, the best treatment for asymptomatic rectal infections 
in MSM is not clear. A number of observational studies, both retrospective and prospective, 
have been reported since 2009. A systematic review and metaanalysis of 8 of these studies 
estimated a pooled efficacy for azithromycin of 82.9%; 5 of the studies also included 
doxycycline, with an estimated pooled efficacy of 99.6% (4). The largest experience among 
these was a retrospective study in Seattle where among MSM with repeat CT testing within 
90 days of treatment, the adjusted relative risk for persistence/recurrence among 
azithromycin treated men was 5.2 (95% CI, 1.3-21) (5). A follow-up report of one of the 
studies in the metaanalysis comprised 532 doxycycline-treated men and women with rectal 
CT, and reported an estimated failure rate of 0.9% (6). Finally, a recent retrospective 
experience among asymptomatic rectal CT in MSM reported an azithromycin efficacy of 
83.6% among 171 azithromycin treated individuals. Of note, biomarkers including ompA 
sequencing and multilocus sequence typing (MLST) and behavioral data were employed to 
help discern treatment failure from reinfection (7). This study also suggests that organism 
load estimated at the index infection prior to treatment is associated with treatment failure.
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Another contribution to this literature is the report in this issue by Smith et al. (8). In a 
prospective observational cohort within the REACT randomized trial in Australia, repeat CT 
infections were sought among men who have sex with women (MSW) (n=89), women who 
have sex with men (WSM) (n=100) and MSM (n=101) who were CT-infected at baseline 
and treated with single-dose azithromycin. In MSW and WSM, urogenital sites were 
sampled, and among MSM, urogenital and rectal sites. The authors employed an algorithm 
which included detailed behaviors, ompA genotyping and MLST to distinguish treatment 
failures from likely reinfections. They found that treatment failures differed between the 
pooled MSW/WSM groups (2.6%) as compared to MSM (8.9%); among MSM most 
treatment failures were at the rectal site. Although the number of repeated infections 
evaluated was relatively small (n=43), the analyses are detailed and carefully done. Initial 
organism load in MSM again was associated with treatment failure. As previously reported, 
CT genotype distributions differed between the pooled MSW/WSM groups and the MSM 
group—another research question is whether this is a product of a largely non-intersecting 
epidemiology, or of bacterial factors that provide a competitive advantage at the rectal site. 
Finally, the study result supports the contention that azithromycin is less effective at the 
rectal site as opposed to genital sites.
The available literature, although observational in nature, points to the possibility of superior 
microbiological effectiveness of doxycycline over azithromycin in rectal CT infections in 
MSM. Recommendations for treatment of asymptomatic rectal CT have shifted to favor the 
doxycycline regimen in both Australian and European guidelines (9, 10). Is this then a 
settled issue? The observational studies above have limitations. Most studies lacked 
biomarkers and many lacked detailed behavioral information to distinguish reinfection from 
treatment failure; some were non-comparative wherein only one treatment regimen was 
reported; several were retrospective; many had high loss-to-follow up rates; some included 
and pooled both men and women; and many included both symptomatic and asymptomatic 
persons. In addition, in some cases diagnostic tests differed, important because culture is less 
sensitive than nucleic acid amplification tests (NAATs). Finally, with the exception of one 
study that compared azithromycin to doxycycline in a before-and –after comparison when 
clinic treatment policy was changed, treatments were not randomized or standardized, and 
the reasons that clinicians selected a regimen are not known.
Despite the fact that the currently available retrospective and prospective observational 
studies all seem to point to a lower response rate to azithromycin, best evidence in the form 
of a randomized controlled trial (RCT) does not yet exist. The good news is that such an 
RCT of azithromycin versus doxycycline for the treatment of asymptomatic rectal infection 
in MSM is underway in Australia. The study protocol has been recently published (11). The 
Rectal Treatment Study aims to recruit 700 MSM with rectal detection of CT by NAAT, 
without symptoms of proctitis. Treatment will be randomized and double-blind. The primary 
outcome is CT detection by NAAT at 4 weeks. Secondary outcomes include use of 
behavioral and molecular analyses as methods for estimating repeated detections that are 
likely treatment failure as opposed to reinfection. The trial began recruiting in August 2016 
with the goal of completing recruitment in 3 years.
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Should doxycycline prove more effective in an RCT setting, many providers would be 
concerned about adherence to the 7 day regimen, and fear that “use-effectiveness” in the real 
world may be less favorable and abrogate any advantage over single-dose therapy. Indeed, 2 
studies using the Medication Event Monitoring System to assess adherence to 7-day 
doxycycline courses in the STD clinic setting suggested low rates (16-25%) of complete 
adherence (12, 13). However, the Bachmann study (13) reported a microbiological treatment 
success of 94% based on NAAT, despite poor adherence. More recently, in the context of an 
RCT comparing azithromycin and doxycycline in the treatment of NGU, a combination of 
written patient logs and computer-assisted self-interviews was used to assess adherence; a 
single missed dose was defined as non-adherence (14). Among men with chlamydial 
urethritis, 1/37 men with complete adherence failed doxycycline, as opposed to 2/10 with 
non-adherence; the 95% confidence interval of adjusted relative risk was very wide 
(1.00-89.2). Perhaps reassuring is that doxycycline efficacy in the observational studies 
ranges from 90.5 to 100%, with 5 of the 6 studies clustered in the 96-100% range (4, 6).
Why might azithromycin be less effective than doxycycline at the rectal site, and why might 
azithromycin be less effective in eradicating CT detected at the rectal site, as opposed to 
urogenital sites? Although differential antibiotic tissue penetration or other factors may be 
involved, it is worth reconsidering the mode of transmission of CT which results in rectal 
shedding. The operative assumption that drives rectal screening recommendations is that 
asymptomatic rectal infections in MSM (and WSM) result from direct inoculation by 
insertive anal intercourse. Many undoubtedly are, but the possibility of acquisition of CT via 
oral sexual activity (fellatio, anilingus) causing asymptomatic gastrointestinal (GI) tract 
infection resulting in rectal shedding must also be considered. Rank and Yeruva (15) 
reviewed the extensive available data for both experimental animal models and for natural 
chlamydial infections in veterinary animals; these demonstrate that an asymptomatic GI 
reservoir, commonly at the cecum, is present in every system studied. The immune response 
to GI involvement appears to wane rapidly despite presence of ongoing infection. Rank and 
Yeruva furthermore have shown that cecal infection in mice commonly fails treatment with 
azithromycin, while genital infection is eradicated; the reason for this disparity is not clear. 
Doxycycline treatment effectively clears both sites. The parallels with available clinical 
observations are striking. It is reasonable to hypothesize that an asymptomatic GI reservoir 
exists in humans as well, and is supported by observations of rectal CT shedding in children 
with trachoma and in persistently infected children after perinatal acquisition. It is thus 
possible that rectal shedding in asymptomatic MSM is due in part to oral acquisition, and 
that a similar mechanism, distinct from genital to rectal autoinoculation, may underlie the 
surprisingly high rectal detection in women who do not report receptive anal intercourse 
(16). A corollary hypothesis is that MSW who engage in oral sexual practices such as 
cunnilingus and anilingus with infected women may acquire and shed CT at the rectal site, 
where direct and autoinoculation of the rectum are unlikely; a pilot study to examine this 
possibility is underway. Regardless, it is clear that much needs to be learned about the 
biological mechanisms involved, and whether GI colonization and rectal shedding requires a 
different treatment approach, not only among MSM, but also among WSM.
For now, if you practice in Australia and Europe, the standard recommendation is to use 
doxycycline as first choice for treatment of asymptomatic rectal infection in MSM. In the 
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United States, until the result of the RCT is known, azithromycin and doxycycline are 
alternatives. A reasonable approach might include engaging the patient in the treatment 
decision process, favoring single dose therapy for those considered unlikely to complete a 7 
day course or who prefer a single dose approach, and providing doxycycline for those who 
prefer what might be a more reliable therapy.
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